Literature DB >> 24107519

[Preclinical biomarker research and patient stratification of molecular target agents: the anti-angiogenic inhibitor Lenvatinib mesylate (E7080)].

Junji Matsui, Yasuhiro Funahashi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24107519     DOI: 10.1254/fpj.142.162

Source DB:  PubMed          Journal:  Nihon Yakurigaku Zasshi        ISSN: 0015-5691


× No keyword cloud information.
  3 in total

1.  Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR/AKT and VEGF signal pathways.

Authors:  Daye Zhang; Yongxiang Zhang; Zeyuan Cai; Ying Tu; Zhansong Hu
Journal:  Exp Ther Med       Date:  2019-11-21       Impact factor: 2.447

2.  Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study.

Authors:  Hiroyuki Iwasaki; Haruhiko Yamazaki; Hirotaka Takasaki; Nobuyasu Suganuma; Hirotaka Nakayama; Soji Toda; Katsuhiko Masudo
Journal:  Oncol Lett       Date:  2018-10-05       Impact factor: 2.967

3.  Combined effects of Lenvatinib and iodine-131 on cell apoptosis in nasopharyngeal carcinoma through inducing endoplasmic reticulum stress.

Authors:  Guoyu Wang; Juhua Zhuang; Jing Ni; Ying Ye; Saifei He; Wei Xia
Journal:  Exp Ther Med       Date:  2018-08-23       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.